These inhibitors suppress the growth of melanoma cells with BRAFV600E but, unlike vemurafenib, do not activate ERK1/2 signalling in cells harbouring mutant KRAS or in cells that have activated tyrosine kinases58. The gene discussed is KRAS; the disease is melanoma.